

Applicant : Yousef Al-Abed
Appl. No. : 10/594,641
Filed : March 28, 2008

Claim Amendments

A listing of the claims, including Claim 1 as herein amended, Claims 10 and 26 as canceled, and new Claims 29-33 as added, is set forth below.

1. (Currently Amended) A method of inhibiting the progression of type 1 diabetes in a mammal having type 1 diabetes ~~or the development of type 1 diabetes in a mammal at risk for type 1 diabetes~~, the method comprising administering to the mammal a pharmaceutical composition comprising an anti-diabetogenic effective amount of an agent to inhibit the progression of type 1 diabetes ~~that inhibits a macrophage migration inhibitory factor (MIF)~~ in the mammal, wherein the agent comprises a binding site of an antibody that binds specifically to macrophage migration inhibitory factor (MIF) ~~the MIF~~.

2. (Canceled).

3. (Previously Presented) The method of claim 1, wherein the agent is an antibody.

4-10. (Canceled).

11. (Original) The method of claim 1, wherein the mammal is a human.

12-26. (Canceled).

27. (Previously Presented) The method of claim 3, wherein the antibody is a monoclonal antibody.

Applicant : Yousef Al-Abed
Appl. No. : 10/594,641
Filed : March 28, 2008

28. (Previously Presented) The method of claim 3, wherein the antibody is a humanized antibody.

29. (New) A method of inhibiting the development of type 1 diabetes in a mammal at risk for type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an amount of an agent effective to inhibit the development of type 1 diabetes in a mammal at risk for type 1 diabetes, wherein the agent comprises a binding site of an antibody that binds specifically to macrophage migration inhibitory factor (MIF).

30. (New) The method of claim 29, wherein the agent is an antibody.

31. (New) The method of claim 29, wherein the mammal is a human.

32. (New) The method of claim 29, wherein the antibody is a monoclonal antibody.

33. (New) The method of claim 29, wherein the antibody is a humanized antibody.